Ra Pharmaceuticals, Inc. (NASDAQ: RARX) today announced positive top-line results from the Company’s Phase 2 clinical trial evaluating zilucoplan for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Ra Pharmaceuticals (RARX) Prices 8.387M Share Common Offering at $15.50/ShDecember 12, 2018 5:49 AM Ra Pharma (RARX) PT Raised to $35 at SunTrust Robinson HumphreyDecember 10, 2018 12:35 PM Ra Pharmaceuticals Announces Positive Top-line Data from Phase 2 Trial of Zilucoplan in Patients with Generalized Myasthenia GravisDecember 10, 2018 7:00 AM Ra Pharmaceuticals (RARX) Secures Development Milestone Payment Under Agreement with Merck (MRK)December 6, 2018 7:34 AM